caa a22 4500 475818547 CHVBK 20180406123816.0 cr unu---uuuuu 170329e20000701xx s 000 0 eng 10.1007/s002280000139 doi (NATIONALLICENCE)springer-10.1007/s002280000139 Efficacy of activated charcoal versus gastric lavage half an hour after ingestion of moclobemide, temazepam, and verapamil [Elektronische Daten] [O. Lapatto-Reiniluoto, K. T. Kivistö, P. J. Neuvonen] Objective: To compare the efficacy of activated charcoal and gastric lavage in preventing the absorption of moclobemide, temazepam, and verapamil 30 min after drug ingestion. Methods: In this randomized cross-over study with three phases, nine healthy volunteers received a single oral dose of 150 mg moclobemide, 10 mg temazepam, and 80 mg verapamil after an overnight fast. Thirty minutes later, they were assigned to one of the following treatments: 25 g activated charcoal as a suspension in 200 ml water, gastric lavage (10 × 200 ml), or 200 ml water (control). Plasma concentrations of moclobemide, temazepam, and verapamil were determined up to 24 h. Results: Activated charcoal reduced the area under the plasma concentration-time curve from 0 h to 24 h (AUC0-24 h) of moclobemide and temazepam by 55% (P < 0.05) and by 45% (P < 0.05), respectively. The AUC0-24 h of verapamil was not significantly reduced by charcoal. Gastric lavage decreased the AUC0-24 h of moclobemide by 44% (P < 0.05), but had no significant effect on that of temazepam or verapamil. The peak plasma concentration (Cmax) of moclobemide, temazepam, and verapamil was reduced by 40%, 29% (P < 0.05), and 16%, respectively, by activated charcoal. Gastric lavage did not significantly decrease the Cmax of any of these drugs. Conclusion: The absorption of moclobemide, temazepam, and verapamil can be moderately reduced by activated charcoal given 30 min after drug ingestion, while gastric lavage seems to be less effective. Springer-Verlag Berlin Heidelberg, 2000 Key words Absorption nationallicence Activated charcoal nationallicence Gastric lavage nationallicence Lapatto-Reiniluoto O. Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland e-mail: outi.lapatto-reiniluoto@nam.fi Fax: +358-9-47174039, FI aut Kivistö K. T. Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland e-mail: outi.lapatto-reiniluoto@nam.fi Fax: +358-9-47174039, FI aut Neuvonen P. J. Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland e-mail: outi.lapatto-reiniluoto@nam.fi Fax: +358-9-47174039, FI aut https://doi.org/10.1007/s002280000139 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280000139 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lapatto-Reiniluoto O. Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland e-mail: outi.lapatto-reiniluoto@nam.fi Fax: +358-9-47174039, FI aut NATIONALLICENCE 700 1- Kivistö K. T. Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland e-mail: outi.lapatto-reiniluoto@nam.fi Fax: +358-9-47174039, FI aut NATIONALLICENCE 700 1- Neuvonen P. J. Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland e-mail: outi.lapatto-reiniluoto@nam.fi Fax: +358-9-47174039, FI aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer